World Sleep Industry ENCYCLOPEDIA

Rooibos Extract

3.1.2

Identity, botanical source, and category boundary

Rooibos extract is made from the leaves and fine stems of Aspalathus linearis (Burm.f.) R.Dahlgren, a legume native to the Cape region of South Africa. The herbal infusion is also called rooibos or red bush, but the plant is not Camellia sinensis and the product is not black tea, green tea, or honeybush. A meaningful label gives the accepted botanical name, plant part, and raw-material type.

Traditional red rooibos is cut, bruised, and subjected to an oxidation step commonly called “fermentation,” whereas green rooibos is dried more rapidly to limit oxidation. In this context, fermentation mainly describes enzyme-mediated oxidation and the development of colour and aroma; it does not require a defined microbial culture. The two raw materials differ in polyphenol profile, flavour, and extraction yield and are not interchangeable merely because both are rooibos.

In WSIC, this entry has code 3.1.2 and sits under “Category 3 Consumer Products and Content / Functional Foods / Botanical Extract Supplements.” It focuses on concentrates prepared with water or another permitted solvent. A tea-bag infusion, instant drink powder, flavoured beverage, isolated aspalathin, cosmetic ingredient, and multi-herb formula are not the same product. Classification does not establish a sedative, hypnotic, or insomnia treatment.

Processing, constituents, and stability

Rooibos contains the dihydrochalcones aspalathin and nothofagin, as well as orientin, isoorientin, vitexin, isovitexin, rutin, and quercetin-related compounds. Aspalathin is often selected as a marker for green rooibos extract, but a “high-aspalathin” specification describes only part of the chemical profile. It does not prove the activity of the full extract, human absorption, or an effect on sleep.

Oxidative processing generally reduces readily altered constituents such as aspalathin while developing a darker colour and different flavour, so green material often retains more aspalathin. Plant type, leaf-to-stem ratio, harvest, particle size, storage, water temperature, time, and material-to-solvent ratio all affect the result. Water extracts, alcohol extracts, and enriched fractions have different profiles, and an in vitro finding from one cannot be transferred directly to another product.

Aspalathin and some other polyphenols can degrade with heat, oxygen, light, and the formulation environment. Spray-drying carriers, acidity, ascorbic acid, sugar, packaging barrier, and storage time may change retention. Extraction ratio, botanical equivalent, mass of dry extract, and mass of a marker are four different quantities. A shelf-life specification should rely on a validated method and real stability data rather than only the highest release value.

Product specification, dose, and comparability

A useful label identifies the species, leaf or fine-stem proportions, green or oxidized raw material, extraction solvent, extraction ratio or botanical equivalent, extract mass per serving, marker constituents, and excipients. A 500 mg capsule does not contain 500 mg of aspalathin and cannot be converted directly into a number of cups. Maltodextrin or cyclodextrin carriers can also make total powder mass greater than the mass of botanical solids.

Human studies have used markedly different materials: a single 400 mL infusion, six cups of traditional rooibos per day, a separated polyphenol-rich fraction, and capsules containing green or traditional water-soluble extracts. These studies mainly examined bioavailability, oxidative-stress variables, or cardiovascular surrogate endpoints; they did not establish a sleep dose. Cups of beverage, milligrams of extract, and milligrams of aspalathin cannot be converted by name or total-polyphenol claims.

The pure rooibos plant is naturally caffeine-free, but blends, flavoured powders, ready-to-drink products, or cross-contaminated goods may contain tea, added caffeine, sugar, or other stimulating ingredients. A product chosen for the evening therefore requires a full ingredient and sugar check. A large fluid load near bedtime may increase nocturia and sleep interruption. Concentrated capsules do not reproduce the hydration or ritual of an infusion and should not be escalated because of a caffeine-free claim.

Sleep evidence and its limitations

There is currently no adequate completed human randomized trial in which an authenticated single-ingredient rooibos extract treated insomnia and was tested against a suitable placebo with standard sleep endpoints. Online experiences, customary evening use, and the absence of caffeine explain why rooibos is often selected as a night-time drink, but they do not show shorter sleep latency, fewer awakenings, more deep sleep, or improvement of a sleep disorder.

A protocol published in 2026 plans a randomized study of green rooibos extract in adults with mild-to-moderate anxiety. Change in anxiety is the primary endpoint, while self-reported sleep quality is secondary. Publishing a protocol does not mean the trial has been completed, and there are no sleep results to assess. Any future change in a secondary endpoint would still require attention to multiple testing, indirect effects through anxiety, product specificity, and the absence of objective sleep measurement.

Existing human work mainly concerns vascular, lipid, redox, or polyphenol-metabolism variables. A 12-person crossover study showed only that small amounts of aspalathin and nothofagin metabolites could be detected after intake; it did not demonstrate delivery to sleep-related brain regions or a hypnotic action. Joining antioxidant assays, changes in angiotensin-converting enzyme, animal stress models, or receptor-binding observations into a “sleep mechanism” exceeds the evidence.

Mechanistic hypotheses and outcome assessment

Experimental literature has discussed polyphenol redox effects, inflammatory signalling, adrenal steroidogenesis, adenosine receptors, and gut-microbial pathways. Results depend on solvent and experimental concentration, and enzyme inhibition or receptor binding in vitro does not show that an oral product reaches the same free concentration. Human absorption work suggests low plasma exposure to intact flavonoids, so a mechanism requires confirmation through metabolites, dose, and clinical outcomes.

When rooibos replaces a caffeinated evening drink, any plausible value comes from reducing the previous caffeine exposure, not from proof that rooibos itself is pharmacologically sedating. Assessment should record the displaced drink, last caffeine time, fluid volume, sugar and alcohol, sleep-onset latency, awakenings, total sleep, next-day alertness, and nocturia. A simple before-and-after comparison remains vulnerable to changes in schedule, expectation, and other behaviours.

Future studies should use a single-ingredient finished product with documented identity, oxidation state, extraction process, and batch fingerprint; match placebo colour and flavour; preregister a primary sleep endpoint; and report all results. Diaries and validated questionnaires may complement wrist actigraphy or polysomnography but do not replace them. Persistent insomnia, snoring with breathing pauses, abnormal sleep behaviours, marked daytime sleepiness, or a mental-health crisis requires professional assessment.

Safety, adverse effects, and special populations

Rooibos infusion has a long history of ordinary food use, and short human studies generally have not reported serious safety problems, but evidence for long-term or higher exposure to concentrated extracts is limited. Gastrointestinal discomfort, headache, rash, or individual allergy may occur. Symptoms may also arise from flavourings, sweeteners, capsule excipients, or contaminants. Swelling of the face, lips, or tongue, wheezing, fainting, or widespread hives requires stopping the product and following local emergency procedures.

A few case reports have described acute liver injury associated with rooibos tea or extract, but their number is too small and formulations and co-exposures are too inconsistent to calculate incidence or assign the same risk to every product. Jaundice, dark urine, pale stools, persistent itching, right-upper-abdominal pain, or unusual fatigue warrants discontinuation and medical care. People with liver disease or multiple herbs, supplements, or potentially hepatotoxic medicines should first obtain professional review.

In vitro work found that certain methanol extracts or constituents affected CYP enzymes, PXR, or drug transporters, but this has not established a clinical interaction for customary oral products. People using narrow-therapeutic-index medicines, anticoagulants, immunosuppressants, antihypertensives, or glucose-lowering treatment should neither stop medicine because of laboratory data nor assume no risk. Pregnancy, breastfeeding, childhood, planned surgery, and impaired liver or kidney function lack adequate concentrated-extract safety data and call for product-specific caution.

Quality, contaminants, and regulation

Quality control should provide traceability from field, botanical identification, harvest, and leaf-to-stem ratio through oxidation or rapid drying, storage, extraction, and filling. Identity can combine macroscopic and microscopic features, DNA methods, quantified aspalathin and other flavonoids, and a chromatographic fingerprint. Processing can degrade DNA, while a single aspalathin assay cannot exclude added marker or foreign plant material, so evidence should be layered.

Rooibos is not itself a typical producer of pyrrolizidine alkaloids, but co-harvested weeds can introduce them. A 2026 European market study also detected varying pyrrolizidine alkaloids, Alternaria toxins, and limited other contaminant signals, showing that a history of tea use does not replace lot testing. Pesticides, toxic elements, microorganisms, mycotoxins, and residual solvents require assessment according to the source, process, and destination market; powdered extracts also require attention to concentration factors.

Packaging should exclude moisture and light, remain sealed, and carry stability-based temperature, expiry, and after-opening limits. The label should disclose all ingredients, serving amount, lot, warnings, storage, and responsible business. “Caffeine-free,” “green,” “high antioxidant,” South African origin, or a stated aspalathin percentage does not prove a sleep benefit. Rules for conventional food, dietary supplements, health foods, and contaminants differ across jurisdictions, and neither a paper nor origin reputation replaces lawful market access and lot-specific compliance records.